Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency

NCT04954469 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT04954469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04954469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2021
Completion date
April 30, 2023
Enrollment
54 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

immune deficiency disease